ENJAYMO
Biological
GENZYME CORPORATION
Total Payments
$1.2M
Transactions
4,506
Doctors
2,561
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $335,658 | 1,792 | 1,346 |
| 2023 | $540,859 | 1,794 | 1,182 |
| 2022 | $357,867 | 920 | 652 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $480,075 | 172 | 38.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $426,843 | 165 | 34.6% |
| Food and Beverage | $122,578 | 3,952 | 9.9% |
| Consulting Fee | $117,557 | 27 | 9.5% |
| Travel and Lodging | $56,532 | 177 | 4.6% |
| Space rental or facility fees (teaching hospital only) | $30,800 | 13 | 2.5% |
Payments by Type
General
$754,309
4,334 transactions
Research
$480,075
172 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Cold Agglutinin Disease Real World Evidence Registry | SANOFI US SERVICES INC. | $338,027 | 0 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion | SANOFI US SERVICES INC. | $94,856 | 0 |
| A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion | SANOFI US SERVICES INC. | $29,942 | 0 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion | GENZYME CORPORATION | $7,500 | 3 |
| A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion | GENZYME CORPORATION | $7,250 | 3 |
| A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP) | GENZYME CORPORATION | $2,500 | 2 |
Top Doctors Receiving Payments for ENJAYMO — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Student in an Organized Health Care Education/Training Program | Chicago, IL | $274.87 | 2 |
| , M.D., PH.D | Anatomic Pathology & Clinical Pathology | Augusta, GA | $273.00 | 3 |
| , AGNP-C | Gerontology | Detroit, MI | $268.38 | 2 |
| , M.D | Hematology & Oncology | Grand Rapids, MI | $268.37 | 2 |
| , MD | Hematology & Oncology | Milwaukee, WI | $268.24 | 2 |
| , DO | Clinical Pathology | Bannockburn, IL | $266.56 | 2 |
| , M. D | Medical Oncology | Houston, TX | $265.30 | 11 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $263.85 | 3 |
| Pedro Vianna | Student in an Organized Health Care Education/Training Program | New York, NY | $258.77 | 2 |
| , MD | Hematology | Boston, MA | $255.78 | 3 |
| , MD | Hematology & Oncology | Kingwood, TX | $255.10 | 10 |
| , M.D | Student in an Organized Health Care Education/Training Program | Maywood, IL | $251.95 | 2 |
| , FNP | Nurse Practitioner | San Gabriel, CA | $247.99 | 5 |
| , MD | Hematology & Oncology | Los Angeles, CA | $246.01 | 3 |
| , NP | Acute Care | Houston, TX | $231.98 | 9 |
| , MD | Hematology & Oncology | Cleveland, TX | $231.66 | 8 |
| , MD | Cardiovascular Disease | Torrance, CA | $231.57 | 2 |
| , FNP | Family | San Antonio, TX | $228.15 | 2 |
| , ARNP | Nurse Practitioner | San Gabriel, CA | $226.46 | 4 |
| , MD | Hematology & Oncology | Bronx, NY | $225.15 | 2 |
| , M.D | Hematology & Oncology | Miami, FL | $220.62 | 2 |
| , D.O | Hematology & Oncology | Burbank, CA | $215.96 | 3 |
| , MD | Hematology | Columbus, OH | $214.87 | 5 |
| Tsvetelina Todorova | Internal Medicine | Chicago, IL | $212.54 | 2 |
| , M.D | Hematology & Oncology | Houston, TX | $212.25 | 8 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $746,808
- SANOFI US SERVICES INC. $462,825
- SANOFI-AVENTIS U.S. LLC $19,141
- RECORDATI_RARE_DISEASES_INC. $5,610
Product Information
- Type Biological
- Total Payments $1.2M
- Total Doctors 2,561
- Transactions 4,506
About ENJAYMO
ENJAYMO is a biological associated with $1.2M in payments to 2,561 healthcare providers, recorded across 4,506 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2022 to 2024. In 2024, $335,658 was paid across 1,792 transactions to 1,346 doctors.
The most common payment nature for ENJAYMO is "Unspecified" ($480,075, 38.9% of total).
ENJAYMO is associated with 6 research studies, including "Cold Agglutinin Disease Real World Evidence Registry" ($338,027).